Thrombo-embolic (blood clotting) events with concurrent low platelets
Up to 17 November 2021, the MHRA had received Yellow Card reports of 426 cases of major thromboembolic events (blood clots) with concurrent thrombocytopenia (low platelet counts) in the UK following vaccination with COVID-19 Vaccine AstraZeneca. Forty-seven of the 426 reports have been reported after a second dose. Of the 426 reports, 215 occurred in females, and 207 occurred in males aged from 18 to 93 years. The overall case fatality rate was 17% with 73 deaths, six of which occurred after the second dose. Cerebral venous sinus thrombosis was reported in 154 cases (average age 46 years) and 272 had other major thromboembolic events (average age 54 years) with concurrent thrombocytopenia.
Up to 17 November 2021, the MHRA had received Yellow Card reports of 27 cases of major thromboembolic events (blood clots) with concurrent thrombocytopenia (low platelet counts) in the UK following use of the COVID-19 Pfizer/BioNTech vaccine. These events occurred in 10 females, and 17 males aged from 18 to 91 years, and the overall case fatality rate was 15% with four deaths reported.
Up to 17 November 2021, the MHRA had received Yellow Card reports of 2 cases of major thromboembolic events (blood clots) with concurrent thrombocytopenia (low platelet counts) in the UK following the use of COVID-19 vaccine Moderna. The 2 events occurred in adult males under the age of 50, and there have been no fatal cases reported.
Myocarditis and pericarditis (Inflammation of the heart)
Up to and including 17 November 2021, we have received 432 reports of myocarditis and 332 reports of pericarditis following use of the COVID-19 Pfizer/BioNTech Vaccine, as well as three reports each of viral pericarditis, viral myocarditis and carditis, two reports for infective pericarditis and one report each of non-infective endocarditis and streptococcal endocarditis. For COVID-19 Vaccine AstraZeneca there have been 153 reports of myocarditis and 189 reports of pericarditis following vaccination up to and including 17 November 2021 as well as seven reports for endocarditis, five reports for viral pericarditis, two reports each for endocarditis bacterial, carditis, viral myocarditis and acute endocarditis and one report each for infectious myocarditis and autoimmune myocarditis. There have been 101 reports of myocarditis, 57 reports of pericarditis and one report of endocarditis following use of COVID-19 Vaccine Moderna up to the same date. Three fatal events have been reported with the COVID-19 Pfizer/BioNTech Vaccine and two fatal events with the COVID-19 Vaccine AstraZeneca. There have been no fatal myocarditis or pericarditis events reported with the COVID-19 Vaccine Moderna to date.
Up to and including the 17 November 2021, the MHRA has received 456 reports of Guillain-Barré Syndrome with the COVID-19 Vaccine AstraZeneca and 26 reports of a related disease called Miller Fisher syndrome. Up to the same date, the MHRA has received 66 reports of Guillain-Barre Syndrome following use of the COVID-19 Pfizer/BioNTech Vaccine and 1 report of Miller Fisher syndrome and for the COVID-19 Vaccine Moderna there have been five reports of Guillain-Barré Syndrome.